CSPC Pharmaceutical Group's (HKG:1093) Regorafenib tablets obtained drug registration approval from China's National Medical Products Administration as it passed the regulator's quality and efficacy consistency evaluation, a Monday bourse filing said.

The drug is indicated for the treatment of patients with metastatic colorectal cancer, gastrointestinal stromal tumor, and hepatocellular carcinoma.